<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03844789</url>
  </required_header>
  <id_info>
    <org_study_id>DCLP5</org_study_id>
    <nct_id>NCT03844789</nct_id>
  </id_info>
  <brief_title>A Study of t:Slim X2 With Control-IQ Technology</brief_title>
  <acronym>DCLP5</acronym>
  <official_title>The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas in Pediatrics: A Study of t:Slim X2 With Control-IQ Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tandem Diabetes Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn whether an investigational automated insulin delivery
      system (&quot;study system&quot;) for children with type 1 diabetes can safely improve blood glucose
      (sometimes called blood sugar) control. The system uses continuous glucose monitoring (CGM),
      an insulin pump, and a software algorithm to automatically give insulin and control blood
      glucose. This is called a &quot;closed-loop control&quot; system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After consent is signed, eligibility will be assessed. Eligible participants not currently
      using an insulin pump and Dexcom CGM with minimum data requirements will initiate a run-in
      phase of 2-4 weeks that will be customized based on whether the participant is already a pump
      or CGM user. Participants who skip or successfully complete the run-in will be randomly
      assigned 3:1 to the use of closed-loop control (CLC group) using t:slim X2 with Control-IQ
      Technology vs. Control Group for 16 weeks. The Control Group will be offered to transition to
      use CLC and the experimental arm will extend their use of CLC for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2019</start_date>
  <completion_date type="Actual">March 20, 2020</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time in range in main study</measure>
    <time_frame>16 weeks</time_frame>
    <description>The primary outcome for the first phase is % time in target range 70-180 mg/dL measured by CGM in CLC group vs. Control Group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGM-measured % above 180 mg/dL [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM-measured mean glucose [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at 16 weeks [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM-measured % below 70 mg/dL [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM-measured % below 54 mg/dL [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM-measured % above 250 mg/dL [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability measured with the coefficient of variation (CV) [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Coefficient of variation- CGM measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM-measured % above 180 mg/dL [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM-measured mean glucose [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c at 28 weeks [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM-measured % below 70 mg/dL [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM-measured % below 54 mg/dL [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM-measured % above 250 mg/dL [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability measured with the coefficient of variation (CV) [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Coefficient of variation- CGM measured</description>
  </secondary_outcome>
  <other_outcome>
    <measure>% in range 70-140 mg/dL [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent - CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>glucose variability measured with the standard deviation (SD) [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Standard Deviation- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>% &lt;60 mg/dL [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>Low blood glucose index [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>index- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoglycemia events (defined as at least 15 consecutive minutes &lt;70 mg\dL) [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>mg/dL- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>% &gt;300 mg/dL [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>High blood glucose index [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>index- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>% in range 70-180 mg/dL improvement from baseline to 16 weeks ≥5% [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>% in range 70-180 mg/dL improvement from baseline to 16 weeks ≥10% [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c &lt; 7.0% at 16 weeks [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent - HbA1c</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c &lt;7.5% at 16 weeks [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent - HbA1c</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c improvement from baseline to 16 weeks &gt;0.5% [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent - HbA1c</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c improvement from baseline to 16 weeks &gt;1.0% [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent - HbA1c</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c relative improvement from baseline to 16 weeks &gt;10% [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent - HbA1c</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c improvement from baseline to 16 weeks &gt;1.0% or HbA1c &lt;7.0% [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Percent - HbA1c</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - Fear of Hypoglycemia Survey (HFS-II) - total score, 2 subscales and 4 factor scores: 1- Behavior (avoidance and maintain high BG), 2- Worry (helplessness and social consequences) [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - Clarke Hypoglycemia Awareness Scores [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - Problem Areas in Diabetes Survey (PAID) [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - INSPIRE survey scores [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - PedsQL Diabetes Module - total score and 5 subscales: 1- Diabetes, 2 - Treatment I, 3 - Treatment II, 4 - Worry, 5 - Communication [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - Pittsburgh Sleep Quality Index (Parent only) [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - System Usability Scale (SUS) [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin - Total daily insulin (units/kg) [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>units/kg</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin - Basal: bolus insulin ratio [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>bolus insulin ratio</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight and Body Mass Index (BMI) [main study]</measure>
    <time_frame>16 weeks</time_frame>
    <description>Weight and BMI</description>
  </other_outcome>
  <other_outcome>
    <measure>Time in range in extension study</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary outcome for the extension phase is improving % time in range 70-180 mg/dL by CGM when Control Group transitions to t:slim X2 with Control-IQ compared with the same group during the Main Phase.</description>
  </other_outcome>
  <other_outcome>
    <measure>% in range 70-140 mg/dL [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent - CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>glucose variability measured with the standard deviation (SD) [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Standard Deviation- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>% &lt;60 mg/dL [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>Low blood glucose index [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>index- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>Hypoglycemia events (defined as at least 15 consecutive minutes &lt;70 mg\dL) [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>mg/dL- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>% &gt;300 mg/dL [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>High blood glucose index [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>index- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>% in range 70-180 mg/dL improvement from 16 weeks to 28 weeks ≥5% [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>% in range 70-180 mg/dL improvement from 16 weeks to 28 weeks ≥10% [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent- CGM measured</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c &lt; 7.0% at 28 weeks [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent - HbA1c</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c &lt;7.5% at 28 weeks [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent - HbA1c</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c improvement from 16 weeks to 28 weeks &gt;0.5% [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent - HbA1c</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c improvement from 16 weeks to 28 weeks &gt;1.0% [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent - HbA1c</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c relative improvement from 16 weeks to 28 weeks &gt;10% [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent - HbA1c</description>
  </other_outcome>
  <other_outcome>
    <measure>HbA1c improvement from 16 weeks to 28 weeks &gt;1.0% or HbA1c &lt;7.0% [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percent - HbA1c</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - Fear of Hypoglycemia Survey (HFS-II) - total score, 2 subscales and 4 factor scores: 1- Behavior (avoidance and maintain high BG), 2- Worry (helplessness and social consequences) [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - Clarke Hypoglycemia Awareness Scores [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - Problem Areas in Diabetes Survey (PAID) [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - INSPIRE survey scores [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - PedsQL Diabetes Module - total score and 5 subscales: 1- Diabetes, 2 - Treatment I, 3 - Treatment II, 4 - Worry, 5 - Communication [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - Pittsburgh Sleep Quality Index (Parent only) [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire - System Usability Scale (SUS) [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin - Total daily insulin (units/kg) [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>units/kg</description>
  </other_outcome>
  <other_outcome>
    <measure>Insulin - Basal: bolus insulin ratio [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>bolus insulin ratio</description>
  </other_outcome>
  <other_outcome>
    <measure>Weight and Body Mass Index (BMI) [extension study]</measure>
    <time_frame>12 weeks</time_frame>
    <description>Weight and BMI</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Closed Loop Control (CLC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem Control-IQ Technology &amp; Dexcom G6 CGM vs Control Group for 16 weeks. Participants randomized to the closed loop control (CLC) arm will use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM for 16 weeks. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible participants not currently using an insulin pump and Dexcom G4, G5 or Dexcom G6 CGM with minimum data requirements will initiate a run-in phase of 2 to 4 weeks that will be customized based on whether the participant is already a pump or CGM user. Participants who skip or successfully complete the run-in will be randomly assigned 3:1 to the use of closed-loop control (CLC group) system using Tandem t:slim X2 with Control-IQ Technology vs Control Group for 16 weeks. All participants will be provided the option of using t:slim X2 with Control-IQ system in a 12 week Extension Phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM</intervention_name>
    <description>Eligible participants will be use the t:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM technology for 16 weeks during the main study. All participants will be provided the option of continue using the t:slim X2 with Control-IQ system in a 12 week Extension Phase. This arm to be uset:slim X2 with Control-IQ Technology &amp; Dexcom G6 CGM</description>
    <arm_group_label>Closed Loop Control (CLC)</arm_group_label>
    <other_name>Experimental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Eligible participants will be use the study Dexcom G6 CGM for 16 weeks during the main study. All participants will be provided the option of using the t:slim X2 with Control-IQ system in a 12 week Extension Phase.</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least
             one year and using insulin for at least 6 months

          2. Familiarity and use of a carbohydrate ratio for meal boluses.

          3. Age ≥ 6 and ≤ 13 years old

          4. Weight ≥25 kg and ≤140 kg

          5. For females, not currently known to be pregnant If female and sexually active, must
             agree to use a form of contraception to prevent pregnancy while a participant in the
             study. A negative serum or urine pregnancy test will be required for all females of
             child-bearing potential. Participants who become pregnant will be discontinued from
             the study. Also, participants who during the study develop and express the intention
             to become pregnant within the timespan of the study will be discontinued.

          6. Living with one or more parent/legal guardian knowledgeable about emergency procedures
             for severe hypoglycemia and able to contact emergency services and study staff.

          7. Willingness to suspend use of any personal closed loop system that they use at home
             for the duration of the clinical trial once the study CGM is in use

          8. Investigator has confidence that the participant can successfully operate all study
             devices and is capable of adhering to the protocol

          9. Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already,
             and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the
             study for participants using to t:slim X2. This includes:

               -  Participants randomized to Control IQ

               -  Participants on the SC group on MDI treatment that will be provided a Tandem pump
                  to switch to CSII

               -  Participates that are already in Continuous Subcutaneous Insulin Infusion (CSII)
                  randomized to SC during the extension phase when transition to Control IQ

         10. Total daily insulin dose (TDD) at least 10 U/day

         11. Willingness not to start any new non-insulin glucose-lowering agent during the course
             of the trial

         12. Participant and parent(s)/guardian(s) willingness to participate in all training
             sessions as directed by study staff.

        Exclusion Criteria:

          1. Concurrent use of any non-insulin glucose-lowering agent other than metformin
             (including glucagon-like peptide [GLP-1] agonists, Symlin, dipeptidyl peptidase 4
             [DPP-4] inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, sulfonylureas).

          2. Hemophilia or any other bleeding disorder

          3. A condition, which in the opinion of the investigator or designee, would put the
             participant or study at risk (specified on the study procedure manual)

          4. Participation in another pharmaceutical or device trial at the time of enrollment or
             during the study

          5. Employed by, or having immediate family members employed by Tandem Diabetes Care,
             Inc., or having a direct supervisor at place of employment who is also directly
             involved in conducting the clinical trial (as a study investigator, coordinator,
             etc.); or having a first-degree relative who is directly involved in conducting the
             clinical trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>13 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melissa J Schoelwer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center, University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UVA Center for Diabetes Technology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2019</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Artificial Pancreas (AP)</keyword>
  <keyword>Control-IQ System</keyword>
  <keyword>Insulin Pump</keyword>
  <keyword>Closed Loop Control (CLC)</keyword>
  <keyword>Continuous Glucose Monitor (CGM)</keyword>
  <keyword>Multiple Daily Injections (MDI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will follow the NIH Data Sharing Policy and Implementation Guidance on sharing research resources for research purposes to qualified individuals within the scientific community.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Generally, data will be made available after the primary publications of each study.</ipd_time_frame>
    <ipd_access_criteria>The Data Sharing Agreements will be formulated by the Steering Committee in collaboration with the NIH Project Scientist Program Official.
In addition, under special arrangements, complete data sets will be provided to industry partners who would use the data for regulatory clearance (PMA - pre-market approval) of the tested artificial pancreas system. This will be done in response to the specific requirements of RFA-DK-14-024 for this project to &quot;…generate data able to satisfy safety and efficacy requirements by regulatory agencies regarding the clinical testing of artificial pancreas device systems&quot; in the target population of people with type 1 diabetes.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

